In contrast, among the 51 metastatic tumor samples, mutations were observed in TP53 (n = 38; 74.5%), FAT1 (n = 12; 23.5%), TERT (n = 10; 19.6%), PIK3CA (n = 9; 17.6%), NSD1 (n = 7; 13.7%), CDKN2A (n = 8; 15.7%), NOTCH1 (n = 8; 15.7%), HGF (n = 5; 9.80%), KMT2D (n = 5; 9.80%), PRKDC (n = 4; 7.84%), and NCOR1 (n = 2; 3.92%). This evidence concerns the gene CDKN2A and neoplasm.